I.a

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

(Fr: PINS aiguë). Acute, generally bilateral and diffuse pneumonitis. More rapid in onset and/or denser, more extensive and severe than pattern Ib. Can be fulminate in the form of diffuse pulmonary interstitial or alveolar opacities and the ARDS picture (see under IIb). BAL is generally lymphocytic and is also indicated to rule out pneumonia due to Pneumocystis, BCG, viruses or other agents particularly in the immunodepressed. Pathology (lung biopsy is not necessary in the majority; before going for the biopsy, please look at PMID 25950989) may disclose dense NSIP, widespread granulomas, or OP depending both on patient and drug. In severe cases pulmonary edema, DAD and/or DAH may develop. Corticosteroid therapy is indicated if patients progress to acute respiratory failure, once an infection has been carefully and resonably ruled out. Transition to pulmonary fibrosis is very uncommon. The boundary between patterns Ia and Ib may be difficult to delineate. See also under IIb

Last update : 01/01/1970
 

Causative drugs

183

Cyclosporine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
IV.k IV - Airway involvement
IV.k - Bronchiectasis
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
XI.ab XI - Miscellaneous
XI.ab - Gingival hypertrophy
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.n XV - Pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern)
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary/systemic infection
1

Cytosine arabinoside - Aracytine - Cytarabine - Ara-C

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse)
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XXIV.a XXIV - Veterinary medicine
XXIV.a - Veterinary: Pneumonitis - Interstitial lung disease
1

Docetaxel

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.j II - Pulmonary edema - Acute lung injury - ARDS
II.j - Transient pulmonary opacities/infiltrates (see also under Iav)
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.r X - Systemic/Distant conditions, syndromes and reactions
X.r - Fluid retention
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
2

E-cigarette - E-vaporizers - ENDS - Vaping - Dabbing

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.aw I - Interstitial/parenchymal lung disease
I.aw - Persistent reduction in diffusing capacity for CO upon resolution of the adverse effect
I.ax I - Interstitial/parenchymal lung disease
I.ax - Chronic pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.u II - Pulmonary edema - Acute lung injury - ARDS
II.u - Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis
III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal)
IV.k IV - Airway involvement
IV.k - Bronchiectasis
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
IV.p IV - Airway involvement
IV.p - Thermal, chemical or caustic airway injury
IV.q IV - Airway involvement
IV.q - Reactive airway dysfunction syndrome (RADS)
IV.t IV - Airway involvement
IV.t - Sptutum production - Bronchorrhea - 'Bronchitis'
IV.v IV - Airway involvement
IV.v - Deterioration/exacerbation of preexisting asthma or COPD
IV.ad IV - Airway involvement
IV.ad - Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.d VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway
VIII.al VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.al - Epiglottitis
VIII.an VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.an - Facial/labial/buccal/oral/dental trauma
VIII.ap VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ap - Airway foreign body
VIII.at VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.at - Gross tracheal inflammation on endoscopy
IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise
IX.af IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.af - Seizures
X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.aq X - Systemic/Distant conditions, syndromes and reactions
X.aq - Relapse or flare of preexisting ulcerative colitis
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.ac XI - Miscellaneous
XI.ac - Thermal skin/dermal injury
XI.ay XI - Miscellaneous
XI.ay - Chest tightness
XI.bc XI - Miscellaneous
XI.bc - Polycythemia
XI.bd XI - Miscellaneous
XI.bd - Nicotine poisoning
XI.be XI - Miscellaneous
XI.be - Burns
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.ag XII - Cardiovascular involvement / toxicity
XII.ag - Bradycardia
XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.p XV - Pathology
XV.p - Path: Exogenous lipoid pneumonia
XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi)
XV.y XV - Pathology
XV.y - Path: Respiratory bronchiolitis (w/wo the RB-ILD-pattern)
XV.ab XV - Pathology
XV.ab - Path: Pulmonary capillaritis
XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy
XV.bi XV - Pathology
XV.bi - Path: Giant-cell interstitial pneumonia (GIP)-pattern
XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.d XVI - Imaging
XVI.d - Imaging: Alveolar opacities or haze with a batwing or butterfly distribution
XVI.g XVI - Imaging
XVI.g - Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.ai XVI - Imaging
XVI.ai - Imaging: A 'tree-in-bud' pattern
XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
XVIII.x XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.x - Eye catcher: A batwing pattern on imaging
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
XIX.d XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.d - BAL: Gross or microscopic bleeding/hemorrhage
XIX.f XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages
XIX.i XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.i - BAL: Oil red O-stainable material in BAL macrophages othen than exogenous lipids
XIX.n XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.n - BAL: Brown-pigmented macrophages
5

Erlotinib

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.ay XVI - Imaging
XVI.ay - Imaging: Asymmetrical, predominantly unilateral involvement
XVI.bw XVI - Imaging
XVI.bw - Imaging: Air or an air crescent around lung tumor or metastase(s)
XXI.e XXI - Rechallenge data
XXI.e - Rechallenge may not necessarily lead to relapse of AE/ILD
1

Everolimus

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.p I - Interstitial/parenchymal lung disease
I.p - Fatal pneumonitis (ILD)
I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain)
VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
2

Fludarabine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
3

G/GM-CSF

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation)
IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism
VI.e VI - Pulmonary vasculopathies
VI.e - Fat/oil embolism - The FES embolism syndrome
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
X.ao X - Systemic/Distant conditions, syndromes and reactions
X.ao - Flare of preexisting vasculitis
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XII.at XII - Cardiovascular involvement / toxicity
XII.at - Aortitis
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
1

Gefitinib

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.ax XII - Cardiovascular involvement / toxicity
XII.ax - Necrotizing myocarditis (w/o evidence for CAD)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.ce XV - Pathology
XV.ce - Path: Necrotizing myocarditis
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
5